Published on
August 28, 2025
- 10:00 GMT
Seneca Therapeutics Announces the Closing of $3.9 million Series B Extension Round
Funding Provides 2+ Years Runway to Complete Phase I/II Trial of Seneca Vally Virus (SVV-001) Currently Underway in High-Grade Neuroendocrine Neoplasms PHILADELPHIA, PA, UNITED STATES, August 28, 2025 /EINPresswire.com/ -- Seneca Therapeutics, Inc., …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
